![](/img/cover-not-exists.png)
CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies: Mavroudis D, Read E, Cottler-Fox M, et al. Blood 88:3223–3229, 1996
Volume:
11
Year:
1997
Language:
english
DOI:
10.1016/s0887-7963(97)80081-8
File:
PDF, 123 KB
english, 1997